Manifest Investing

FDA Approval: Obesity Drug Race Update

Date: Monday, April 23 · 12:00 AM - 1:00 AM UTC
Location: Online

Space is limited. Register today to reserve your seat!

Manifest Investing will run a two-part webcast on the drug approval process. Hosted by Hugh McManus, the presentation will focus on two drug applications awaiting approval by the Food and Drug Administration: Qnexa from Vivus, Inc. [NASDAQ:VVUS] and Lorqess from Arena Pharmaceuticals, Inc. [NASDAQ:ARNA]. Each drug addresses the growing problem of obesity and weight management.

The presentation will focus mainly on the drug approval process rather than on the companies themselves. Participants will be introduced to the FDA website and where to look for useful information; the approval process will be examined as well as other websites where useful information is often posted. Each presentation will last for an hour with a portion of the time of the end of answers and questions.

There will be a follow up discussion on the MI website.

Quality Legend:
Blue	Excellent with quality greater than 80.
Green	Good with quality between 60 and 80.
Neutral	Average or below average with quality between 20 and 60.
Red	Poor with quality less than 20.
Companies with less than 10 years of history are penalized by 5 points per year.
PAR Legend:
Green	PAR is within the target range of MIPAR +5-10%, currently 5.1%-10.1%
Yellow	PAR is above the target range of MIPAR +10%, currently 10.1%
PAR	Projected Annual Return
MIPAR	The Manifest Investing Median PAR of all stocks in the database.
Company Name Legend:
*	Not covered by Value Line Standard Edition.
b	Uses price-to-book value for valuation purposes.
P/CF	Uses price-to-cash flow for valuation.